Početna › Kronična limfocitna leukemija › Texas
Kliničke studije za Kronična limfocitna leukemija u državi Texas
38 studija za Kronična limfocitna leukemija traži sudionike na lokacijama u državi Texas.
Gradovi u državi Texas
Službeni tekst studije (engleski)
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
U tijeku regrutacijaFaza 1
Do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT01853631Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Hendrick Medical Center, Abilene
U tijeku regrutacijaFaza 3
Od 65 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 40 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT05334069A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Houston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT06542250A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Texas Oncology Baylorcharles A Sammons Cancer Center, Dallas
- Texas Oncology San Antonio Medical Center Usor, San Antonio
- Texas Oncology Tyler, Tyler
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Md Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT05006716A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Texas Oncology Tyler, Tyler
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Baylor Scott and White Health, Temple
- Texas Oncology Tyler, Tyler
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06846671A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Md Anderson Cancer Center, Houston
- Texas Oncology Palestine Cancer Center, Palestine
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06973187A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- PatientCare Clinical Research LLC ( Site 5435), Sugar Land
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Texas Oncology - Central/South Texas ( Site 8008), Austin
- The Center for Cancer and Blood Disorders ( Site 0032), Fort Worth
- Texas Oncology - San Antonio ( Site 8006), San Antonio
- i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT06136559A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Texas Oncology - Paris, Fort Worth
- US Oncology - Texas Oncology, Kyle
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07218341Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- The University of Texas MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Texas Oncology - Center South, Austin
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 17. ruj 2026. · NCT07221500Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 10. ruj 2026. · NCT04169737A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Houston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT06564038Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Baylor University Medical Center, Dallas
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT03666000Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Baylor Scott & White Health, Dallas
- MD Anderson, Houston
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT04588922Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Texas Oncology - West Texas, Midland
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 31. kol 2026. · NCT07516093Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Texas Oncology - Northeast, Tyler
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT07520006A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Lumi Research, Kingwood
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 17. kol 2026. · NCT05254743Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1/2
Od 13 do 90 godina · Oba spola · Ažurirano 6. kol 2026. · NCT06533579A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
- UT Southwestern Medical Center, Dallas
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 31. srp 2026. · NCT06708897Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
- MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 30. srp 2026. · NCT06967610A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. srp 2026. · NCT05131022A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
- Texas Oncology - Sammons Cancer Center, Dallas
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 12. lip 2026. · NCT07271667A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- USO-Texas Oncology-Central/South Texas, Austin
- Sarah Cannon Research Institute/SCRI, The Woodlands
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 19. svi 2026. · NCT06588478Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 13 godina i više · Oba spola · Ažurirano 5. svi 2026. · NCT04771572The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
U tijeku regrutacijaFaza 1/2
Od 12 do 95 godina · Oba spola · Ažurirano 15. tra 2026. · NCT04329728A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Texas Oncology - Austin Midtown /ID# 268152, Austin
- University of Texas - Southwestern Medical Center /ID# 266528, Dallas
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 9. tra 2026. · NCT06428019A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 20. ožu 2026. · NCT04830137A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- University of Texas MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 2. ožu 2026. · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- University of Texas MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 2. ožu 2026. · NCT06876649Study of SGR-1505 in Mature B-Cell Neoplasms
- University of Texas Southwestern, Dallas
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. velj 2026. · NCT05544019AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 10. pro 2025. · NCT05602363A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- SCRI, San Antonio
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 14. stu 2025. · NCT05643742A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University of Texas Southwestern Medical Center, Dallas
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2025. · NCT05780034Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- UT Southwestern Medical Center, Dallas
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 4. kol 2022. · NCT04502394Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.